Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Relmada Therapeutics, Inc. - Common Stock (NQ: RLMD ) 0.3830 +0.0208 (+5.74%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,246,990 Open 0.3600 Bid (Size) 0.3850 (2) Ask (Size) 0.3917 (10) Prev. Close 0.3622 Today's Range 0.3556 - 0.4100 52wk Range 0.3416 - 7.223 Shares Outstanding 17,472,986 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Wednesday's Pre-Market Session December 04, 2024 Via Benzinga Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why December 04, 2024 Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals. Via Benzinga Performance YTD -91.24% -91.24% 1 Month -86.79% -86.79% 3 Month -88.64% -88.64% 6 Month -87.23% -87.23% 1 Year -89.89% -89.89% More News Read More Nasdaq Surges 150 Points; ISM Services PMI Falls In November December 04, 2024 Via Benzinga Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results December 04, 2024 Via Benzinga Topics Stocks Exposures US Equities A Look Ahead: Relmada Therapeutics's Earnings Forecast November 06, 2024 Via Benzinga RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024 August 07, 2024 Via InvestorPlace Recap: Relmada Therapeutics Q4 Earnings March 19, 2024 Via Benzinga Earnings Outlook For Relmada Therapeutics March 18, 2024 Via Benzinga Earnings Outlook For Relmada Therapeutics November 07, 2023 Via Benzinga Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday June 05, 2024 Via Benzinga 7 Penny Biotech Stocks to Triple Your Investment May 28, 2024 Via InvestorPlace RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024 May 08, 2024 Via InvestorPlace RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023 March 19, 2024 Via InvestorPlace Earnings Scheduled For March 19, 2024 March 19, 2024 Via Benzinga Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying February 01, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 04, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 04, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday October 04, 2023 Via InvestorPlace 12 Health Care Stocks Moving In Thursday's Pre-Market Session September 21, 2023 Via Benzinga Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study September 20, 2023 Via Benzinga Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm August 11, 2023 From Bragar Eagel & Squire Via GlobeNewswire FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says August 07, 2023 Via Benzinga Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm August 06, 2023 From Bragar Eagel & Squire Via GlobeNewswire 7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick July 31, 2023 Via InvestorPlace Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm July 26, 2023 From Bragar Eagel & Squire Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
